Collegium Pharmaceutical posted a record quarter and raised its outlook. For Q3 2025, the company reported $209.4 million in net product revenue, up 31% year over year, and $133.0 million in adjusted EBITDA, up 27%. Strength in both its ADHD product Jornay PM and its pain portfolio lifted results, prompting full-year guidance increases to $775–$785 million in net product revenue and $460–$470 million in adjusted EBITDA. The company ended the quarter with $285.9 million in cash, cash equivalents, and marketable securities and continued capital returns through an accelerated share repurchase under a $150 million authorization.
The strategic signal is clear: an execution-first specialty pharma can still compound growth around established, often scrutinized, therapeutic categories if it pairs targeted differentiation with disciplined payer strategy and relentless field focus. The open question is durability. Collegium’s portfolio is concentrated in controlled substances, where policy, quota, and utilization management can shift quickly. Turning record quarters into a defensible multi-year growth arc will depend on how well the company converts clinical and real-world advantages into sustained access and prescriber habit.
Jornay PM delivered $41.8 million in quarterly revenue, with prescriptions up 20% year over year and prescribers reaching an all-time high of 27,700. The back-to-school tailwind helped, but the thesis hinges on a differentiated profile—an evening-dosed methylphenidate designed for early-morning symptom control—translating into daily-life benefits that matter to families and clinicians. For payers managing escalating ADHD utilization and stimulant shortages, the product’s niche value proposition must be backed by pragmatic outcomes and adherence data to justify formulary position and step therapy exceptions. For HCPs, education will be pivotal in defining patient archetypes for which Jornay PM offers utility beyond lower-cost generics.
In pain, the quarter underscored diversification across mechanisms and brands. Belbuca generated $58.3 million, up 10%; Xtampza ER delivered $50.5 million, up 2%; and the Nucynta franchise reached $54.8 million, up 21%. Buprenorphine’s credibility as a “responsible pain” option continues to rise, and abuse-deterrent formulations remain a lever for payer engagement, even as pricing and rebate pressures persist. Collegium leaned into real-world evidence, presenting multiple posters and publications across Painweek and peer-reviewed journals to reinforce effectiveness and functional outcomes. That medical narrative is not just academic; it is a contracting asset in a category where payers are tightening controls and regulators are vigilant.
Commercially, the model is textbook specialty optimization: high-ROI promotion, precision access tactics, and selective capital deployment. The company is paying down debt, repurchasing shares, and signaling its readiness to expand its neuropsychiatry and pain footprint through business development. Across the sector, cash-generative specialty players are consolidating undercapitalized assets, prioritizing near-term revenue over early-stage R&D risk. For competitors, Collegium’s rising scale in ADHD detailing and pain contracting raises the bar for share capture; for payers, it foreshadows more arduous negotiations anchored in RWE and adherence metrics.
Two catalysts will define the next leg. First, access stability amid heightened utilization management in ADHD and evolving DEA quota dynamics. Second, portfolio resilience against generic pressure and policy shifts in opioids. If Collegium can translate its growing RWE portfolio into payer wins while using its balance sheet to diversify beyond controlled substances, it could turn quarterly momentum into a sturdier growth platform. The sharper question for 2026 is whether the company deploys its cash flow to acquire assets that de-risk category concentration, or doubles down on its current franchises to press its competitive advantage.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
